Background In addition to renin-angiotensin system inhibition (RAS), corticosteroids are recommended for patients who have immunoglobulin A nephropathy (IgAN) with ]1 g/day proteinuria. Tonsillectomy plus corticosteroid pulse therapy (TSP) had been reported as more effective in producing clinical remission of IgAN than just oral-corticosteroid (OS) or steroid-pulse (SP) therapy-but that remained unconfirmed. Accordingly, this study compared the effects of TSP, corticosteroid therapies, and RAS on a multicenter, large-scale, long-term cohort. Methods 1127 biopsy-proven IgAN patients with chronic kidney disease (CKD), G1-3, treated in our hospitals March 1981-December 2013 with TSP (n = 209), SP (n = 103), OS (n = 300), or RAS, alone (n = 515), were followed until end-stage renal disease (ESRD) or death, renal survival compared by treatment and proteinuria level. Hazard ratios (HRs) of ESRD were analyzed after adjusting for sex, age, BMI, eGFR, albumin, proteinuria, hematuria, blood pressure, medications, and renal-biopsy year, with propensity-score-matched analyses performed. Results With TSP as referent, the overall HRs of SP, OS, and RAS were, respectively, 1. Conclusion TSP may decrease the risk of ESRD in IgAN patients better than other therapies in CKD G1-2, with proteinuria ]1.0 g/gCre, while outcome was similar to SP in CKD G3, or with proteinuria \1.0 g/gCre.
Introduction
Immunoglobulin A nephropathy (IgAN) has for some time been the most common cause of end-stage renal disease (ESRD) around the world-most markedly in Japan and other Asian countries [1] [2] [3] . Many studies in Asian and Western countries published from the 1980s to the 2010s showed that 10-year overall renal survival among IgAN patients was very similar-between 80 and 85 %-no matter which of many therapies was used [4, 5] . However, several studies, including controlled trials, reported that corticosteroid treatment was more effective than just reninElectronic supplementary material The online version of this article (doi:10.1007/s10157-015-1194-z) contains supplementary material, which is available to authorized users.
angiotensin system inhibitors (RAS), especially for IgAN patients with proteinuria ]1 g/day and an estimated glomerular filtration rate (eGFR) [50 ml/min/1.73 m 2 [6] [7] [8] [9] . Based on these findings, the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis recommended use of corticosteroids as oral steroids (OS) or steroid pulse (SP) for patients with persistent proteinuria at that level, even after 3-6 months of optimal supportive care including RAS and blood pressure control [10] . In this KDIGO guideline, tonsillectomy plus corticosteroid pulse therapy (TSP) is not recommended routinely for treatment of IgAN whereas the Japanese Clinical Practice Guideline for IgAN recommends it as grade C1.
In 2001, Hotta et al. reported that TSP was more effective that SP, alone, in achieving clinical remission [11] , and other reports followed, including a controlled trial, suggesting good clinical remission rates in patients who received TSP [12] [13] [14] [15] [16] . In addition, a recent meta-analysis suggested a better clinical remission rate for patients with TSP than for those without tonsillectomy [17] .
On the other hand, a recent randomized controlled trial did not find that TSP, compared with SP, alone, had a beneficial effect in attenuating hematuria during 12 months of observation, and concluded that TSP's impact on renal function remains unknown [3] .
All these findings-sometimes inconclusive and even contradictory-impelled the present multicenter, long-term cohort study designed to investigate the comparative effect of TSP and other therapies in preventing ESRD.
Methods

Patient population
The data were obtained from medical records of patients treated at our four hospitals in the Tokyo metropolitan area March 1981-December 2013. The patients had biopsyproven IgAN with an eGFR ]30 ml/min/1.73 m 2 , and were 18 years or older. Patients with a history of renal transplantation or of any other renal disease were excluded.
Pathological diagnosis had been performed by at least two observers, with histological grading of biopsy specimens evaluated using the Oxford IgAN classification [18] and the Japanese criteria published by the Japanese IgAN Study Group, with pathological grades (H-grades) I-IV representing, respectively, \25 %, 25-49 %, 50-74 %, and ]75 % of glomeruli that exhibit cellular/fibrocellular crescents (active lesions) or fibrous crescents or global/ segmental sclerosis (chronic lesions) [19] -or a combination thereof.
Patients' demographic data had been obtained at the time of renal biopsy. All laboratory data and medicationsincluding serum albumin (Alb), serum creatinine, total cholesterol, hemoglobin (Hb), systolic and diastolic blood pressure, proteinuria, hematuria, body weight, use and dose of prednisone, use of RAS, anticoagulants, and/or antiplatelets-had been noted before treatment, at 3, 6, and 12 months after, and every subsequent year until the end of follow-up. All laboratory values had been measured by the automated, standardized methods used in our hospitals within 24 h after drawing blood samples. If the Jaffe method had been used to measure serum creatinine, the values were converted, for our analyses, to those for enzyme assays. Proteinuria was categorized into three groups: \0.5 g/gram creatinine (gCre) or urine dipstick with (-) or (±); 0.5-0.99 g/gCre or (?); and ]1.0 g/gCre or (2?). Hematuria was categorized into four groups: \5/ high power field (HPF) or urine dipstick with (-) or (±); 5-10/HPF or (?); 10-29/HPF or (2?); and ]30/HPF or (3?). Renal-biopsy year was categorized as the 1980s, 1990s, or 2000s. The primary outcome of this study was initiation of dialysis as indication of ESRD, with all patients followed until ESRD, death, or end of follow-up. The eGFR was calculated by the formula for Japanese patients devised by Matsuo et al. [20] . The study's protocol was approved by institutional review boards in each hospital.
Statistical analysis
We categorized patients into four groups-TSP, SP, OS, and RAS-based on their initial treatment and/or the treatment in use at [50 % of their follow-ups. The TSP protocol was three courses of a 3-day pulse of methylprednisolone, 0.5 g/day, administered 2-4 weeks after tonsillectomy, followed by oral corticosteroid at an initial dose of 30 mg every other day, gradually tapered by 5 mg every 2 months, then discontinued 12 months after the initial therapy. The original SP protocol was a 3-day pulse of methylprednisolone administered in months 1, 3, and 5 in addition to 0.5 mg/kg of oral prednisone every other day. With both TSP and SP, however, the number of methylprednisolone pulses could be reduced to one or two courses depending on the patient's condition or clinician's preference. Data were summarized using proportions and means (±SD) as appropriate. Categorical variables were analyzed with the Chi-squared or Fisher's exact test, continuous variables compared using Student's t test, the Mann-Whitney U test, or ANOVA. Cumulative survival was estimated with Kaplan-Meier survival curves, and compared by log-rank test. Cox proportional hazard models were used to obtain hazard ratios (HRs) and a 95 % confidence interval (95 % CI) for ESRD. In the Cox model 1, each HR was adjusted for the risk grade calculated by the IgA scoring system [21] , medications (use of RAS, anticoagulants, and/or antiplatelets), and renal-biopsy year (RBY). In model 2, each HR was adjusted for sex, age, body mass index (BMI), eGFR, Alb, proteinuria, hematuria, blood pressure control, medications, and RBY. In model 3, each HR was adjusted for model-2 factors plus pathological grade.
To minimize selection bias for IgAN treatment, propensity score-matched analyses were performed to balance patients' background characteristics, including treatment group, age, sex, eGFR, Alb, proteinuria, hematuria, Hb, blood pressure control, medications, RBY, and pathological grade. To estimate the propensity score, we used a logistic regression model for the choice of treatment as a function of the background characteristics detailed above. Each patient with RAS was matched with a patient with TSP, SP, and OS with nearest-neighbor matching on the logit scale. All analyses used Stata Ò SE version 13.1 (StataCorp, College Station, TX).
Results
Of the 1840 patients screened, 1127 met the study criteria. Table 1 shows the characteristics of eligible IgAN patients who received TSP (n = 209), SP (n = 103), OS (n = 300), and RAS, alone (n = 515). Mean age was lower in the TSP and OS groups (p \ 0.01) than in the other two. The proportion of chronic kidney disease (CKD), stages G1 and 2 (eGFR ]60 ml/min/1.73 m 2 ), and proteinuria \1.0 g/gCre was highest in the TSP group while the proportion of CKD, G3 (eGFR 30-59 ml/min/1.73 m 2 ), and proteinuria ]1.0 g/ gCre was highest in the SP group (p \ 0.01). Of those in the TSP group, 65.1 % also received RAS, as did 77.7 % with SP, and 56.3 % with OS (p \ 0.01). The mean initial dose of daily oral prednisolone with TSP, SP, and OS was, respectively, 17 ± 6, 26 ± 13, and 28 ± 11 mg (p \ 0.001). Methylprednisolone pulse courses were reduced for 33 % of the TSP patients, 66 % with SP. The mean follow-up duration was 8.3 ± 6.4 years overall, 7.0 ± 4.4 years with TSP, 6.6 ± 5.4 with SP, 10.4 ± 7.3 with OS, and 8.0 ± 6.4 with RAS, alone.
Renal survival by decade
As shown in Table 2, Table 2 ), indicating that renal outcome for IgAN patients improved over the decades. Interestingly, this survival rate was similar to that reported in European and Asian countries in the 1980s and 1990s (around 80-85 %) [4] . Better renal outcome with TSP/SP may contribute to the overall improvement of renal outcome by decade.
Renal survival with each treatment
Comparing renal survival after renal biopsy for each group, 10-and 15-year survival was, respectively, with TSP, Table 2 ). The overall renal survival curve with TSP was significantly better than with other groups by log rank: p = 0.04 vs. SP; p \ 0.001 vs. OS or RAS (Fig. 1a) . When analyzing patients by proteinuria, the curves of all four groups were similar with proteinuria \1.0 g/gCre or \0.5 g/gCre, but when proteinuria was ]1.0 g/gCre, renal survival with TSP was better than with OS (p = 0.02) or RAS (p = 0.03) (Fig. 1b-d) , and 10-year survival better with TSP than with SP (p = 0.02) although, after 10 years, the curves of those two groups became similar-partially due to the limited number of patients with TSP and SP who were followed up [10 years. In addition, similar renal outcomes were observed when we divided patients treated with TSP and SP by the number of methylprednisolone pulses they received, whether one or two. However, the adjusted HR of patients treated with three or more pulses in model 3-with one or two as referent-was 0.09 (0.02-0.51, p = 0.006), suggesting that treatment with three or more courses of pulse may be beneficial.
Then we compared HRs of ESRD in each treatment group using Cox models with TSP as referent ( Although the HRs were not significantly different between TSP and SP, these data suggested better renal prognosis for patients with TSP than with the other treatments, and were consistent throughout the models.
Since use of TSP was wide-spread after the end of the 90s, and many kinds of RAS appeared after 2000, we did sub-analyses of patients after the year 2000 (n = 550). In these sub-analyses, the survival curve of TSP was significantly better than that of RAS (p B 0.01), and showed a better trend than those of SP (p = 0.13) and OS (p = 0.11) ( Figure S1 ). Also, in the Cox analyses, with TSP as referent, the overall HRs in model 2 were, for SP, 0.95 
Comparison of treatments by renal function and proteinuria
Next, to determine the best candidates for TSP, we analyzed the HR of each treatment by CKD stage and level of proteinuria with TSP as referent. As detailed in Fig. 2 , when proteinuria was ]1.0 g/gCre, the HR with TSP was significantly better than with OS or RAS-e.g., in model 2, respectively, 5.04 (1.44-17.67) and 7.23 (1.98-26.40)-and showed a better trend than with SP, which was 2.99 (0.71-12.54), the results consistent across the models. However, for patients whose proteinuria was \1.0 g/ gCre-or whose CKD was G3-the HR with TSP was only slightly better than with OS or RAS and similar to that with SP, suggesting that tonsillectomy, in addition to SP, may not confer any additional benefit to those patients.
Propensity score-matched analyses
Since we did not control the assignment of treatments, the treatment groups may have differences in their observed covariates that could lead to biased estimates of the treatment effect. So to minimize selection bias for choice of treatment, we performed propensity-score matching to balance patients' background characteristics, including age, sex, eGFR, Alb, Hb, proteinuria, hematuria, blood pressure control, medications (use of RAS, anticoagulants or antiplatelets), and pathological grade. After matching, a similar distribution of characteristics was observed between TSP and other treatments (Supplementary (Table 3) . So the HRs in the propensity score-matched population were very similar to those in the whole population, and those of TSP were the best among the four treatments in patients with proteinuria ]1.0 g/gCre, but similar to those of the other treatments in patients with proteinuria \1.0 g/gCre.
Discussion
In this multicenter cohort study, we found that TSP was more strongly associated with lower HR of ESRD than SP, OS, or RAS in IgAN patients whose proteinuria was ]1.0 g/gCre, but not in patients with proteinuria \1.0 g/ gCre. In addition, we found that corticosteroid treatments (SP or OS) were better than RAS, alone, in patients with proteinuria ]1.0 g/gCre, which is consistent with previous findings [6] [7] [8] [9] and what is suggested in the 2012 KDIGO clinical practice guideline [10] . There had been some reports showing that the effect of TSP on clinical remission of IgAN was superior to that of corticosteroid treatments, including SP [11] [12] [13] ; but the evidence showing the preventive effect of TSP on ESRD was not strong, mainly because those studies lacked statistical power due to their short observation periods and limited number of participants. Recently, the first metaanalysis was reported showing that the effect of TSP on clinical remission was superior to that of SP, and showing the possible preventive effect of tonsillectomy on ESRD [17] . Although this was the first study suggesting the possible preventive effect of TSP on ESRD, the number of patients was limited (n = 873) and diverse treatment procedures were included. To our knowledge, the present study is the largest ever conducted comparing treatments of IgAN with ESRD targeted as an outcome. Moreover, because our cohort, while large-scale, was treated at only four hospitals, treatment regimens were relatively well controlled compared with nationwide or meta-analysis cohorts. Interestingly, the HR of ESRD this study found when TSP was the treatment-with corticosteroid (SP or OS) as referent-was 0.19 (0.06-0.64), which is very similar to the reported pooled odds ratio of 0.25 (0.12-0.52) in the meta-analysis [17] .
There are several new findings in this study. First, the patients who are most probably the best candidates for TSP were identified. Our study showed that they were the patients with CKD G1 and G2 whose proteinuria was ]1.0 g/gCre; it also showed that TSP may be better thanand at least equal to-SP for patients with CKD G3 and proteinuria ]1.0 g/gCre, and distinctly better than OS and RAS. Going by one finding in the meta-analysis cited above that suggested tonsillectomy to reduce the rate of ESRD [17] , TSP may be more effective than SP, alone, in patients with IgAN. But, at this point, we cannot posit the superiority of TSP over SP because, in our study, the difference was not significant due to the wide range in HRs of 95 % CI. And in patients with proteinuria \1.0 g/gCre, the HRs with TSP, SP, and OS were not significantly better than with RAS, again due to the wide range of 95 % CI, suggesting that there is not enough evidence at this point to choose TSP over RAS for those patients. Second, our study showed an improvement in overall 10-year renal survival during the last three decades. In the 1980s, 1990s, and 2000s, 10-year renal survival for our cohort was, respectively, 79.6 % (72.8-84.9), 84.6 % (81.3-87.4), and 89.5 % (85.9-92.3). The reason for this may be that, in addition to improvement of the various treatment regimens (TSP, SP, etc.), the clinical trend toward total CKD management of IgAN has contributed to better renal prognosis in these patients because improvement of renal survival was also seen in within each treatment group. Therefore, third, a general trend in overall 10-year renal survival with TSP may be inferred. Our multicenter large-scale cohort [3, 11, 12] . Note that our consistent results among analyses in the multiple models-adjusted for possible confounders-and among propensity score-matched analyses, show the robustness of our results. The benefit of TSP to patients with mild IgAN has not been confirmed. Our study did not find that TSP was superior to SP for these patients. Perhaps the effect of TSP over SP in patients with mild IgAN may be small because such patients have less immune abnormality associated with mucosa; or an inability to detect the difference between these two treatments may be inherent to the situation. Because the reported annual eGFR decline in patients with proteinuria B1.0 g/day was only -1.0 ml/ min/1.73 m 2 /year [5] , the instance of end-stage renal disease among such patients may be small-which, in our study, may have compromised detection of the difference between the TSP and SP groups. Recently, Komatsu et al. reported that TSP led to clinical remission more effectively than other treatments for IgAN patients with mild proteinuria (0.4-1.0 g/day) [22] . In their study, the rate of clinical remission was significantly higher with TSP than SP (71.7 vs. 44.4 %). However, because the number of patients in their study was very limited (especially in the Follow-up years Follow-up years Fig. 3 Comparison of renal survival in propensity score-matched cohorts by treatment. The p values were calculated by log-rank test.
Upro proteinuria g/gCre, TSP tonsillectomy plus steroid pulse therapy, SP steroid pulse therapy, OS oral steroid therapy, and RAS inhibitors of renin-angiotensin system Upro proteinuria g/gCre, TSP tonsillectomy plus steroid pulse therapy, SP steroid pulse therapy, OS oral steroid therapy, RAS inhibitors of renin-angiotensin system, eGFR estimated glomerular filtration rate SP group: n = 9), and they merged patients who had received SP and OS in the same group, one must await larger studies to assess the efficacy of TSP over SP in patients with mild IgAN. Furthermore, although tonsillectomy is a relatively non-invasive operation, one patient in our cohort who received TSP experienced postoperative hemorrhage, requiring blood transfusion. And it has been reported that the rate of post-tonsillectomy hemorrhage was 2.3-7.7 % [23, 24] . Therefore, at this point, SP might be the better choice for patients with mild IgAN. There are several limitations to this study. First, selection biases in treatment may exist. Because of the nature of cohort studies, treatment protocols were not uniformly defined, which may obscure the actual effect of treatment. Indeed, younger patients with preserved renal function were more likely to receive TSP than other therapies-and more likely to receive it than were other groups-which may affect renal outcome in this study. However, the consistent results-including propensity score-matched analyses-may overcome this inherent disadvantage of cohort studies. Second, since the follow-up continued for many years, selection bias involving drop-out or trend of treatment in each era may exist. For example, steroid use was initiated in the 1980s and TSP in the early 2000s. Although we adjusted by renal-biopsy years, and observed similar results in propensity score-matched analyses, one needs to be careful in assessing these results. Finally, the 95 % CIs of our HRs were relatively widely ranged. Although ESRD is considered the gold standard for renaloutcome studies, because it takes so long to become definite, this hard outcome needs a particularly large sample size for stable analysis, so its use may decrease study power in long follow-up studies with their inherently large drop-out rate. Some soft outcomes have been proposed as proxies for ESRD. But there is no direct evidence that, for instance, the doubling of serum creatinine or any other soft outcome is surely predictive of ESRD. Recently, the association of decline in eGFR with subsequent risk of ESRD was reported in the general CKD population [25] , and this may be another possible factor in identifying the best candidates for TSP, though it is still unclear whether this association is same among different races or renal diseases. In any case, while ESDR remains the standard, analyses that involve an even larger IgAN population than ours are needed to confirm the best candidates for TSP in greater detail.
In conclusion, our multicenter large-scale cohort study demonstrated the effectiveness of TSP for patients with IgAN, and, for now, identified the best candidates for the treatment. If IgAN patients have CKD G1 or G2 with proteinuria ]1.0 g/gCre, TSP should be considered if they are not otherwise contraindicated for it, while SP, alone, may be the best option for patients with proteinuria \1.0 g or CKD G3.
